100 related articles for article (PubMed ID: 187101)
1. Clinical immunoadjuvant studies with tilorone, DEAA fluorene (RMI 11,002da), and Corynebacterium parvum and some observations on the role of host resistance and herpes-like lesions in tumor growth.
Regelson W
Ann N Y Acad Sci; 1976; 277(00):269-87. PubMed ID: 187101
[No Abstract] [Full Text] [Related]
2. Experimental encephalitis caused by herpes simplex virus: comparison of treatment with tilorone hydrochloride and phosphonoacetic acid.
Fitzwilliam JF; Griffith JF
J Infect Dis; 1976 Jun; 133 Suppl():A221-5. PubMed ID: 180204
[TBL] [Abstract][Full Text] [Related]
3. Further observations on the inhibition of tumor growth by Corynebacterium parvum with cyclophosphamide. V. Comparison of the effects of tilorone hydrochloride, levamisole, methanol-soluble fraction of Mycobacterium butyricum, BCG, and a nonviable aqueous ether extract of Brucella abortus preparation in treatment of mice with tumors.
Fisher B; Linta J; Hanlon J; Saffer E
J Natl Cancer Inst; 1978 Feb; 60(2):391-9. PubMed ID: 413929
[No Abstract] [Full Text] [Related]
4. Immunomodulation of host resistance to experimental viral infections in mice: effects of Corynebacterium acnes, Corynebacterium parvum, and Bacille calmette-guérin.
Glasgow LA; Fischbach J; Bryant SM; Kern ER
J Infect Dis; 1977 May; 135(5):763-70. PubMed ID: 192811
[TBL] [Abstract][Full Text] [Related]
5. Antitumor action of pyran copolymer and tilorone against Lewis lung carcinoma and B-16 melanoma.
Morahan PS; Munson JA; Baird LG; Kaplan AM; Regelson W
Cancer Res; 1974 Mar; 34(3):506-11. PubMed ID: 4812258
[No Abstract] [Full Text] [Related]
6. Corynebacterium parvum as an immunotherapeutic anticancer agent.
Scott MT
Semin Oncol; 1974 Dec; 1(4):367-78. PubMed ID: 4620441
[No Abstract] [Full Text] [Related]
7. Defective in vitro lymphoproliferative responses to herpes simplex virus in patients with frequently recurring herpes infections during the disease-free interval.
Kirchner H; Schwenteck M; Northoff H; Schöpf E
Clin Immunol Immunopathol; 1978 Nov; 11(3):267-74. PubMed ID: 213220
[No Abstract] [Full Text] [Related]
8. [The use of Corynebacterium parvum in pleurodesis].
Helin T; Haahtela T
Duodecim; 1988; 104(4):262-5. PubMed ID: 3168834
[No Abstract] [Full Text] [Related]
9. [Pleural effusion. Local treatment by Corynebacterium parvum].
Serrou B; Cupissol D
Nouv Presse Med; 1980 Jun; 9(25):1777-8. PubMed ID: 7383874
[No Abstract] [Full Text] [Related]
10. Comparative effects of Corynebacterium parvum, Brucella abortus extract, Bacillus Calmette-Guérin, glucan, levamisole, and tilorone with or without cyclophosphamide on tumor growth, macrophage production, and macrophage cytotoxicity in a murine mammary tumor model.
Fisher B; Gebhardt M
Cancer Treat Rep; 1978 Nov; 62(11):1919-30. PubMed ID: 728912
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic trial of tilorone in ALS: lack of benefit in a double-blind, placebo-controlled study.
Olson WH; Simons JA; Halaas GW
Neurology; 1978 Dec; 28(12):1293-5. PubMed ID: 366454
[TBL] [Abstract][Full Text] [Related]
12. Effects of tilorone hydrochloride on experimental flavivirus infections in mice.
Vargin VV; Zschiesche W; Semenov BF
Acta Virol; 1977 Mar; 21(2):114-8. PubMed ID: 17279
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant intralesional and systemic Corynebacterium parvum immunotherapy for surgically treated head and neck cancer.
Beatty JD; Terz JJ; Brown PW; Lawrence W; Schuller GB; Kaplan AM
Surg Forum; 1978; 29():155-7. PubMed ID: 401122
[No Abstract] [Full Text] [Related]
14. [Monitoring natural killer cell activity in the blood of patients with malignant pleural effusion after intrapleural administration of Corynebacterium parvum].
Marel M; Pospísil M; Fiserová A; Melínová L; Skácel Z; Bednár M
Cas Lek Cesk; 1990 Apr; 129(16):498-500. PubMed ID: 2340567
[TBL] [Abstract][Full Text] [Related]
15. The mode of inhibition of herpes simplex and vesicular stomatitis ocular viral infections in the rabbit and hamster by an interferon inducer tilorone dihydrochloride.
Tokumaru T
Res Commun Chem Pathol Pharmacol; 1975 Jun; 11(2):289-301. PubMed ID: 168623
[TBL] [Abstract][Full Text] [Related]
16. [Immunotherapy today. II. Immunostimulating therapy].
D'Amelio R
Riv Med Aeronaut Spaz; 1978; 41(1):75-114. PubMed ID: 93770
[No Abstract] [Full Text] [Related]
17. Mitogenicity of Corynebacterium parvum for mouse lymphocytes.
Zola H
Clin Exp Immunol; 1975 Dec; 22(3):514-21. PubMed ID: 817854
[TBL] [Abstract][Full Text] [Related]
18. The effect of nonspecific immune stimulation with Corynebacterium parvum and polidin on the Ehrlich ascites tumor growth.
Todoruţiu C; Rişcă R; Daicoviciu D; Mulea R
Morphol Embryol (Bucur); 1982; 28(1):77-83. PubMed ID: 6461826
[TBL] [Abstract][Full Text] [Related]
19. Resistance to Marek's disease. Effect of Corynebacterium parvum and Marek's tumor cell vaccines on tumorigenesis in chickens.
Donahoe J; Kleven S; Eidson C
J Natl Cancer Inst; 1978 Apr; 60(4):829-33. PubMed ID: 24754
[TBL] [Abstract][Full Text] [Related]
20. The biological activity of the synthetic polyanion, pyran copolymer (diveema, MVE, 46015) and the heterocyclic bis DEAE fluorenone derivative, tilorone and congeners: clinical and laboratory effects of these agents as modulators of host resistance.
Regelson W
Pharmacol Ther; 1981; 15(1):1-44. PubMed ID: 7038712
[No Abstract] [Full Text] [Related]
[Next] [New Search]
